ALLMedicine™ Langerhans Cell Histiocytosis Center
Research & Reviews 808 results
https://doi.org/10.1097/RLU.0000000000004267
Clinical Nuclear Medicine; Wang L, Zhang Y et. al.
May 12th, 2022 - Widespread cutaneous involvement of Langerhans cell histiocytosis is rare. Here, we report the case of a patient with cutaneous Langerhans cell histiocytosis, which showed a large number of small high 18F-FDG-avid foci all over the body skin on PE...
https://doi.org/10.1016/j.amjms.2022.04.014
The American Journal of the Medical Sciences; Volis I, Livneh I et. al.
Apr 27th, 2022 - Langerhans cell histiocytosis (LCH) is an uncommon clonal proliferation of myeloid progenitor cells, it is especially rare in adults. We present a case of multi-system LCH in a 53-year-old woman, the sole symptom of which was prolonged, non-resolv...
https://doi.org/10.1097/PAI.0000000000001029
Applied Immunohistochemistry & Molecular Morphology : AIMM; Wegher LSM, Kazmarek LM et. al.
Apr 19th, 2022 - There are several activated forms of macrophages: 2 main groups are designated M1 and M2. While M1 macrophages have proinflammatory, bactericidal, and phagocytic functions and are the dominant phenotype observed in the early stages of inflammation...
https://doi.org/10.1177/10935266221078501
Pediatric and Developmental Pathology : the Official Jour... Baig A, Albrecht S et. al.
Apr 15th, 2022 - Congenital Langerhans cell histiocytosis (LCH) (formerly called Letterer-Siwe disease) is characterized by a clonal proliferation of Langerhans cells occurring in children at birth and manifests typically with multifocal cutaneous lesions, hepatos...
https://doi.org/10.1016/j.transproceed.2022.02.037
Transplantation Proceedings; Abba ME, Żegleń S et. al.
Apr 13th, 2022 - Langerhans cell histiocytosis (LCH) is a rare inflammatory disorder of myeloid dendritic cells with mutations involving KRAS, BRAF and/or NRAS, and MAP2K1 genes. We describe the case of a 58-year-old female previous smoker with multifocal LCH invo...
Guidelines 1 results
https://doi.org/10.1016/j.mayocp.2019.02.023
Mayo Clinic Proceedings; Goyal G, Young JR et. al.
Sep 2nd, 2019 - Histiocytic neoplasms, a rare and heterogeneous group of disorders, primarily include Erdheim-Chester disease, Langerhans cell histiocytosis, and Rosai-Dorfman disease. Due to their diverse clinical manifestations, the greatest challenge posed by ...
Clinicaltrials.gov 15 results
https://clinicaltrials.gov/ct2/show/NCT05092815
Jan 4th, 2022 - The purpose of this study was to assess safety, efficacy and PK in adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) given HLX208 (BRAF V600E inhibitor).
https://clinicaltrials.gov/ct2/show/NCT04079179
Sep 2nd, 2021 - Histiocytic disorders are diseases caused by misfunctioning or buildup of particular immune cells called histiocytes. Many histiocytic disorders (LCH, juvenile xanthogranuloma (JXG), Erdheim-Chester disease (ECD), and Rosai-Dorfman Disease (RDD)) ...
https://clinicaltrials.gov/ct2/show/NCT02281760
Aug 31st, 2021 - Erdheim-Chester Diseases (ECD) is a very rare non-Langerhans cell histiocytosis of unknown origin and pathogenesis. It has been reported mainly in adult males over the age of 40 years, although cases have been reported in females as well. Children...
https://clinicaltrials.gov/ct2/show/NCT02670707
Jun 4th, 2021 - To be eligible to participate in this study, patients physician must have determined that they have LCH which is not treatable by surgical intervention or observation alone. If patient chooses to participate in this study, they will be assigned ra...
https://clinicaltrials.gov/ct2/show/NCT02285582
Mar 9th, 2021 - Histiocytoses are rare diseases caused by an excess of cells called Histiocytes, which can infiltrate the skin, bones, lungs, liver, spleen and the central nervous system. These disorders can range from localized involvement that resolves spontane...
News 27 results
https://www.medscape.com/viewarticle/963817
Dec 1st, 2021 - Guidelines for the treatment of Langerhans cell histiocytosis (LCH) were published in November 2021 by the National Comprehensive Cancer Network (NCCN) in Journal of the National Comprehensive Cancer Network.[1] Decisions regarding treatment of LC...
https://www.onclive.com/view/selumetinib-response-not-driven-by-mapk-expression-in-pediatric-and-aya-refractory-solid-tumors
Jun 10th, 2021 - Selumetinib did not elicit clinical activity in pediatric and young adult patients with refractory cancers who had actionable mutations in the RAS/RAF/MAPK1/2-ERK pathway, according to cohort findings from the phase 2, single-arm National Cancer I...
https://www.onclive.com/view/cog-to-assess-targeted-therapies-in-a-variety-of-nhl-clinical-trials
Dec 20th, 2020 - Birte Wistinghausen, MD The Children's Oncology Group (COG) is currently involved in 5 studies exploring targeted therapies in non-Hodgkin lymphoma (NHL) that could eventually change the face of pediatric NHL treatment.1 Birte Wistinghausen, MD,...
https://www.onclive.com/view/radiotherapy-in-the-modern-era-in-the-management-of-langerhans-cell-histiocytosis
Dec 5th, 2020 - Rupen Garg, BS EXPERT'S PERSPECTIVE: Bradford Hoppe, MD, MPH Associate Professor, University of Florida Proton Therapy Institute Why is this article contemporary? One concern for utilizing radiotherapy (RT) is the potential for toxicity,...
https://www.medpagetoday.com/infectiousdisease/covid19/86021
Apr 19th, 2020 - Early reports on the COVID-19 pandemic allude to a cytokine storm or hyper-inflammation, especially in patients who succumbed to the illness. These conclusions are based on elevated levels of ferritin and other inflammatory markers, drawing compar...